Svenson

In 2013 Svenson continued to adapt to the new economic environment, with special emphasis on cost reduction, including a more efficient use of human resources, the monitoring of workload per individual, the closing of non-profitable centres and the optimization of the acquisition cost per new client. The company continues to operate under difficult economic conditions with consumer spending down significantly. Nevertheless, it is continuing to diversify its product offering towards a more profitable mix: growth in the medical division based in micrographs and dermatology treatments. In March 2014, an agreement was signed for the sale of Svenson to a European investment portfolio managed by BNP Paribas.